Mycophenolate Mofetil Accord Healthcare Ireland

Mycophenolate Mofetil, the active ingredient in Mycophenolate Mofetil Accord Healthcare Ireland, is an immunosuppressant presented as an oral dosage form for oral use. It is used to prevent organ transplant rejection and to treat certain autoimmune conditions such as lupus nephritis.

GNH USA supplies Mycophenolate Mofetil Accord Healthcare Ireland as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mycophenolate Mofetil acts on the immune system to reduce abnormal lymphocyte activity, making it valuable in several transplant and autoimmune settings. - Organ transplant rejection: helps prevent the immune system from attacking the transplanted organ. - Lupus nephritis: reduces kidney inflammation associated with systemic lupus erythematosus. - Autoimmune diseases: suppresses abnormal immune activity in conditions such as certain vasculitides.

Mycophenolate Mofetil may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: occasional upset stomach or feeling of queasiness. - Diarrhea: loose stools that may be watery. - Headache: mild to moderate head pain. - Infections: increased susceptibility to upper respiratory or urinary infections.

Serious or Rare Side Effects: - Leukopenia: significant drop in white blood cells, raising infection risk. - Hepatic toxicity: abnormal liver enzyme elevations or hepatitis. - Progressive multifocal leukoencephalopathy (PML): rare but potentially fatal brain infection.

Before initiating therapy, several safety considerations are recommended. - Monitor blood counts: regular CBC testing to detect leukopenia or anemia. - Assess renal function: adjust dosing in renal impairment. - Avoid live vaccines: immunosuppression may reduce vaccine efficacy. - Pregnancy risk: category D; discuss potential fetal risks with the prescriber. - Store at below 25°C: keep in the original pack, protect from moisture.

Mycophenolate Mofetil can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Live vaccines: may cause infection due to suppressed immunity. - Other antimetabolites (e.g., azathioprine): additive bone‑marrow suppression. - Strong CYP3A4 inducers (e.g., rifampin): markedly reduce mycophenolate exposure. - Antacids containing aluminum or magnesium: decrease oral absorption.

Moderate Interactions (Monitor Closely): - Warfarin: may increase INR and bleeding risk. - ACE inhibitors or ARBs: monitor renal function and potassium levels. - Non‑live vaccines: immune response may be attenuated, requiring follow‑up serology.